Bringing a sterile injectable product from development to commercialization requires a seamless scale-up process—one that minimizes risk, optimizes efficiency, and ensures regulatory success. In this exclusive webinar, experts from August Bioservices will discuss the critical factors that make or break a successful scale-up, sharing insights from a CDMO’s unique perspective.

Our discussion will focus on three key perspectives:

• • Talent & Expertise: Scaling a business requires specialized expertise across multiple disciplines—from formulation development and process optimization to analytical testing and regulatory compliance. We will explore how the right talent at each phase of building a sterile injectable CDMO ensures that the right people are in the right roles at the right time, mitigating bottlenecks before they arise.
• • Equipment & Facility Readiness: Having the right infrastructure in place is crucial to scaling a CDMO. We’ll discuss how state-of-the-art manufacturing lines, flexible capacity, and facilities designed to meet global regulatory requirements play a role in accelerating scale-up while maintaining product quality and regulatory compliance.
• • Customer-Centric Approach: A CDMO is more than just a service provider, it’s a strategic partner. We’ll highlight why close collaboration with clients throughout the development and scale-up process is essential, ensuring alignment on goals, timelines, and quality expectations. From early-stage development through commercial launch, our team works as an extension of our clients’ teams, and that collaborative approach ultimately serves to de-risk the process and enable long-term program success.

This webinar will provide a detailed look inside Kindeva's state-of-the-art aseptic fill-finish facility. Attendees will learn how Kindeva's advanced capabilities, cutting-edge technology (including the OPTIMA sterile fill finish system) and commitment to progression can streamline the development and manufacturing of injectable drug products. The successful completion of the first registration batches at Bridgeton will also be discussed. The webinar will close by highlighting how Kindeva can act as a strategic partner, helping pharmaceutical companies navigate the complexities of bringing life-saving injectable therapies to market.

This webinar will cover the intricacies of liposomal topical semi-solid products, focusing on their role in enhancing drug delivery through the skin. It will begin with an overview of semi-solid dosage forms, explaining their complex two-phase structure and how liposomes integrate into these formulations.

Key topics will include skin anatomy, drug penetration pathways, and how liposomes improve dermato-pharmacokinetics compared to conventional semi-solid formulations. The session will also explore factors affecting drug release from liposome-based formulations, the influence of flux on skin permeation, and the benefits and challenges of developing these advanced delivery systems.